Ipsen Entered into a Definitive Merger Agreement to Acquire Epizyme for ~$247M
Shots:
- Ipsen to acquire all outstanding shares of Epizyme at $1.45/share for an initial consideration of ~$247M along with 1 CVR/share representing a premium of ~144% at Epizyme's closing price of $0.60 over 30 days. The transaction is expected to close at the end of Q3’22
- The holder of each CVR will receive $0.30/CVR upon reaching $250M in net sales of Tazverik (Ex-Japan & Greater China) by Dec 2026 & $0.70/CVR upon US approval for Tazverik & R2 in FL by Jan 2028
- The acquisition combines Ipsen’s capabilities & resources in oncology with Epizyme’s to bolster Tazverik's growth (currently in the P-III (SYMPHONY-1) trial, results are expected in 2026) for FL. Ipsen will also acquire EZM0414 in P-I/Ib trial for r/r MM & DLBCL
Ref: Bussinesswire | Image: Ipsen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
